MeSH D007680 - kidney neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Bevacizumab | Abevmy |  | 2021-04-21 |  |  |
| Bevacizumab | Lextemy |  |  |  |  | |
| Roche | Bevacizumab | Avastin |  | 2005-01-12 | $1,988.958 M | Q4/22-Q3/23 |
| Pfizer | Bevacizumab | Zirabev |  | 2019-06-27 | $424 M | Y2023 |
| Eli Lilly | Vinblastine | Velban |  | 1982-01-01 |  |  |
| Hospira | Vinblastine | Vinblastine |  | 1987-08-18 |  |  |
| Amneal Pharmaceuticals | Bevacizumab | Alymsys |  | 2022-04-13 |  |  |
| Bristol Myers Squibb | Nivolumab | Nivolumab BMS |  | 2015-07-20 |  |  |
| Nivolumab | Opdivo |  | 2014-12-22 | $9,664 M | Q3/24-Q2/25 | |
| Nivolumab, Relatlimab | Opdualag |  | 2022-03-18 | $1,023 M | Q3/24-Q2/25 | |
| Hikma Pharmaceuticals | Vinblastine | Vinblastine |  | 1987-04-09 |  |  |
| Celltrion | Bevacizumab | Vegzelma |  | 2022-09-27 |  |  |
| Genentech | Bevacizumab | Avastin |  | 2004-02-26 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
80%83/104
Phase 2
20%31/154
Phase 3
23%9/40
Approved: 4Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use